- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02176148
Cutaneous Lupus Medication Experience Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cutaneous lupus is a chronic, relapsing auto-immune disease that negatively impacts patients' quality of life. As there are many safe topical therapies that require daily use to be effective, and adherence to medication remains a common problem in dermatology, it is worthwhile to reliably measure adherence to medication in patients with cutaneous lupus. By elucidating barriers to effective control of cutaneous lupus with topical medications, we can improve patient care and guide interventions that will avoid the use of systemic therapy which often has more side effects.
The primary aim is to determine adherence to topical and systemic lupus treatment. Subjects will receive standard of care therapy (low potency and high potency topical corticosteroids) and systemic therapy when clinically appropriate. Adherence to medications will be monitored electronically in all subjects. The following hypothesis is to be tested: Non-adherence to topical and systemic medication contributes to treatment failure in patients with cutaneous lupus.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest University School of Medicine - Department of Dermatology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Any male or female 12 years or older of age with a diagnosis of cutaneous lupus by a dermatologist
- Capable of understanding and willing to provide a signed and dated written voluntary informed consent before any protocol specific procedures are performed
- Able to complete the study and comply with study instructions, including attending all study visits
Exclusion Criteria:
- Individuals younger than 12 years of age
- Known allergy or sensitivity to study medication
- Inability to complete all study-related visits
- Introduction of any other prescription medication, topical or systemic, for cutaneous lupus while participating in the study
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Lupus control standard-of-care
Each person enrolled will be given fluocinonide 0.05% cream to apply twice daily to active areas.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Adherence Measures
Time Frame: up to 6 month
|
There will be interim measures taken after the baseline measure at month 1, month 3, and at end point month 6.
|
up to 6 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Severity Measures
Time Frame: 6 months
|
Assessments will be taken at baseline, month 1, month 3, and at end point month 6.
|
6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: William W Huang, MD, MPH, FAAD, Wake Forest University Health Sciences
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00026573
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cutaneous Lupus
-
BiogenRecruitingSubacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus ErythematosusUnited States, Italy, Korea, Republic of, Taiwan, Argentina, Chile, Spain, Canada, Serbia, France, Germany, Japan, Brazil, United Kingdom, Puerto Rico, Bulgaria, Portugal, Switzerland, Philippines, Saudi Arabia, Sweden, Mexico, Poland, Hunga... and more
-
BiogenEnrolling by invitationSubacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus ErythematosusSpain, United States, Sweden
-
AmgenTerminatedCutaneous Lupus | LupusUnited States, Australia, Canada
-
University of PennsylvaniaRecruitingCutaneous Lupus Erythematosus (CLE)United States
-
Novartis PharmaceuticalsCompletedSubacute Cutaneous Lupus ErythematosusGreece, Germany, Italy
-
David WeinsteinTerminated
-
Bristol-Myers SquibbRecruitingLupus Erythematosus, Discoid | Lupus Erythematosus, Subacute CutaneousUnited States, Mexico, Russian Federation, Australia, Argentina, Poland, France, Germany, Taiwan
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Gilead SciencesRecruitingCutaneous Lupus Erythematosus (CLE)United States, Spain, Czechia, Germany
-
University of PennsylvaniaCelgene CorporationCompletedCutaneous Lupus Erythematosus (CLE)United States
Clinical Trials on fluocinonide 0.05% cream
-
Northwestern UniversityBayerTerminated
-
Arcutis Biotherapeutics, Inc.CompletedAtopic DermatitisUnited States, Canada
-
Arcutis Biotherapeutics, Inc.CompletedAtopic Dermatitis (Eczema)United States
-
Arcutis Biotherapeutics, Inc.Active, not recruitingAtopic Dermatitis EczemaUnited States, Canada
-
Wake Forest UniversityCompleted
-
Wake Forest UniversityMedicis Pharmaceutical CorporationCompletedAtopic DermatitisUnited States
-
G & W Laboratories Inc.CompletedPlaque PsoriasisUnited States
-
Wake Forest University Health SciencesMedicis Pharmaceutical CorporationCompletedAtopic DermatitisUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)Completed
-
NeoStrata Company, Inc.Massachusetts General HospitalUnknownEczema | Dermatitis, AtopicUnited States